文献速递冠心病

高出血风险心肌梗死患者冠脉支架术后缩短抗血小板治疗

Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

MASTER DAPT 试验随机纳入 4,579 例高出血风险患者,支架术后 1 个月双联抗血小板治疗(DAPT)后随机分为缩短组(停 DAPT,单抗 11 个月;口服抗凝者 5 个月)或非缩短组(DAPT 至少 3 个月)。在急性或近期心肌梗死亚组(n=1,780)中,缩短组与非缩短组的 NACE 和 MACCE 无差异,出血事件显著减少。

要点

  • 高出血风险心梗患者支架术后 1 个月 DAPT 后缩短抗血小板治疗,NACE 与 MACCE 不增加
  • 缩短抗血小板治疗显著降低 BARC 2、3 或 5 型出血风险
  • 急性或近期心梗与非心梗患者的交互作用无统计学意义

核心结论

  • 高出血风险急性或近期心肌梗死患者支架术后 1 个月 DAPT 后缩短抗血小板治疗,NACE 和 MACCE 发生率与非缩短策略相似,且出血显著减少。

研究设计与样本

  • MASTER DAPT 试验随机纳入 4,579 例高出血风险患者,支架术后 1 个月 DAPT 后随机分为缩短组或非缩短组,按指数操作时有无急性或近期心肌梗死分层。

主要发现

  • 急性或近期心梗患者(n=1,780)缩短组与非缩短组 NACE 的 HR 为 0.83(95%CI 0.61-1.12),MACCE 的 HR 为 0.86(95%CI 0.62-1.19)。
  • 无急性或近期心梗患者(n=2,799)缩短组与非缩短组 NACE 的 HR 为 1.03(95%CI 0.77-1.38),MACCE 的 HR 为 1.13(95%CI 0.80-1.59)。
  • NACE 和 MACCE 的交互作用 P 值分别为 0.31 和 0.25。
  • 急性或近期心梗患者 BARC 2、3 或 5 型出血的 HR 为 0.65(95%CI 0.46-0.91),无急性或近期心梗患者为 0.71(95%CI 0.54-0.92),交互作用 P=0.72。

临床怎么用

  • 高出血风险心梗患者支架术后 1 个月 DAPT 后可考虑缩短抗血小板治疗以降低出血风险,同时不增加缺血事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal duration of antiplatelet therapy (APT) after coronary stenting in patients at high bleeding risk (HBR) presenting with an acute coronary syndrome remains unclear. OBJECTIVES: The objective of this study was to investigate the safety and efficacy of an abbreviated APT regimen after coronary stenting in an HBR population presenting with acute or recent myocardial infarction. METHODS: In the MASTER DAPT trial, 4,579 patients at HBR were randomized after 1 month of dual APT (DAPT) to abbreviated (DAPT stopped and 11 months single APT or 5 months in patients with oral anticoagulants) or nonabbreviated APT (DAPT for minimum 3 months) strategies. Randomization was stratified by acute or recent myocardial infarction at index procedure. Coprimary outcomes at 335 days after randomization were net adverse clinical outcomes events (NACE); major adverse cardiac and cerebral events (MACCE); and type 2, 3, or 5 Bleeding Academic Research Consortium bleeding. RESULTS: NACE and MACCE did not differ with abbreviated vs nonabbreviated APT regimens in patients with an acute or recent myocardial infarction (n = 1,780; HR: 0.83; 95% CI: 0.61-1.12 and HR: 0.86; 95% CI: 0.62-1.19, respectively) or without an acute or recent myocardial infarction (n = 2,799; HR: 1.03; 95% CI: 0.77-1.38 and HR: 1.13; 95% CI: 0.80-1.59; Pinteraction = 0.31 and 0.25, respectively). Bleeding Academic Research Consortium 2, 3, or 5 bleeding was significantly reduced in patients with or without an acute or recent myocardial infarction (HR: 0.65; 95% CI: 0.46-0.91 and HR: 0.71; 95% CI: 0.54-0.92; Pinteraction = 0.72) with abbreviated APT. CONCLUSIONS: A 1-month DAPT strategy in patients with HBR presenting with an acute or recent myocardial infarction results in similar NACE and MACCE rates and reduces bleedings compared with a nonabbreviated DAPT strategy. (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; NCT03023020).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Smits, Frigoli, Vranckx, et al. Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk. J Am Coll Cardiol. 2022. PMID: 36137672. doi:10.1016/j.jacc.2022.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。